Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review

References

• Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2019 report. 2019 cited 2018 Dec 18. Available from: http://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf
   Google Scholar
• Nannini LJ, Poole P, Milan SJ, et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 Aug 30;8:CD006826.
   PubMedGoogle Scholar
• Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Sep 12;9:CD006829.
   PubMedGoogle Scholar
• Barrecheguren M, Monteagudo M, Ferrer J, et al. Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. Respir Med. 2016;111:47–53.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Segreti A, Bettoncelli G, et al. Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. Prim Care Respir J. 2011;20:291–298.
   PubMedGoogle Scholar
• Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med. 2012;106:989–997.
   PubMed Web of Science ®Google Scholar
• Glaab T, Banik N, Rutschmann OT, et al. National survey of guideline-compliant COPD management among pneumologists and primary care physicians. COPD. 2006;3:141–148.
   PubMedGoogle Scholar
• Jochmann A, Neubauer F, Miedinger D, et al. General practitioner’s adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort study. Swiss Med Wkly. 2010;140. DOI:10.4414/smw.2010.13053
   Web of Science ®Google Scholar
• Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904.
   PubMed Web of Science ®Google Scholar
• AstraZeneca Sweden. Symbicort forte Turbuhaler 320 micrograms/9 micrograms/inhalation, inhalation powder: summary of product characteristics 2018 cited 2019 Aug 12. Available from: https://docetp.mpa.se/LMF/Symbicort%20forte%20Turbuhaler%20inhalation%20powder%20ENG%20SmPC_09001be6800240ca.pdf.
   Google Scholar
• AstraZeneca UK Limited. Symbicort Turbohaler 200/6 inhalation powder summary of product characteristics Bedfordshire, UK. 2018 cited 2019 Jul 24. Available from: https://www.medicines.org.uk/emc/product/1327/smpc.
   Google Scholar
• Chiesi Pharmaceuticals BV Foster®: Chiesi, Nederland.; 2018 cited 2019 Aug 12. Available from: https://www.chiesi.nl/en/foster.
   Google Scholar
• GlaxoSmithKline (Ireland) Limited. Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed: summary of product characteristics 2018 cited 2019 Aug 7. Available from: https://www.medicines.org.uk/emc/product/5226/smpc.
   Google Scholar
• GlaxoSmithKline (Ireland) Limited. Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed: summary of product characteristics 2019 cited 2019 Aug 7. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/relvar-ellipta.
   Google Scholar
• GlaxoSmithKline UK. Seretide 100 Accuhaler: summary of product characteristics 2018 cited 2019 Aug 7. Available from: https://www.medicines.org.uk/emc/product/5504/smpc.
   Google Scholar
• Chiesi Limited. Fostair NEXThaler 100/6 Summary of product characteristics Manchester, UK: emc; 2018 cited 2019 Aug 7. Available from: https://www.medicines.org.uk/emc/product/3317/smpc.
   Google Scholar
• Teva BV Aerivio Spiromax 50 micrograms/500 micrograms inhalation powder: summary of product characteristics 2017 cited 2019 Aug 7. Available from: https://www.ema.europa.eu/en/documents/product-information/aerivio-spiromax-epar-product-information_en.pdf.
   Google Scholar
• Calverley PMA, Kuna P, Monso E, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med. 2010;104:1858–1868.
   PubMed Web of Science ®Google Scholar
• Stynes G, Svedsater H, Wex J, et al. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy. Respir Res. 2015;16:25.
   PubMed Web of Science ®Google Scholar
• Blais L, Forget A, Ramachandran S. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin Ther. 2010;32:1320–1328.
   PubMed Web of Science ®Google Scholar
• Cope S, Capkun-Niggli G, Gale R, et al. Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease–a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2011;6:329–344.
   PubMed Web of Science ®Google Scholar
• Dal NR, Eandi M, Pradelli L, et al. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2:169–176.
   PubMedGoogle Scholar
• Dekhuijzen PNR, Batsiou M, Bjermer L, et al. Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device. Respir Med. 2016;120:54–63.
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Gray J, Edwards SJ, et al. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract. 2011;65:764–774.
   PubMed Web of Science ®Google Scholar
• Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346:f3306.
   PubMed Web of Science ®Google Scholar
• Larsson K, Janson C, Lisspers K, et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Intern Med. 2013;273:584–594.
   PubMed Web of Science ®Google Scholar
• Partridge MR, Schuermann W, Beckman O, et al. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis. 2009;3:1–11.
   PubMedGoogle Scholar
• Perrone V, Sangiorgi D, Buda S, et al. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting. Int J Chron Obstruct Pulmon Dis. 2016;11:2749–2755.
   PubMed Web of Science ®Google Scholar
• Tricco AC, Strifler L, Veroniki -A-A, et al. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis. BMJ Open. 2015;5:e009183.
   PubMed Web of Science ®Google Scholar
• Wang CY, Lai CC, Yang WC, et al. The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients’ life quality with COPD in Taiwan (IMPACT) study. Int J Chron Obstruct Pulmon Dis. 2016;11:2775–2783.
   PubMed Web of Science ®Google Scholar
• Yang -H-H, Lai -C-C, Wang Y-H, et al. Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist. Int J Chron Obstruct Pulmon Dis. 2017;12:2477–2485.
   PubMed Web of Science ®Google Scholar
• Roggeri A, Micheletto C, Roggeri DP. Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study. Int J Chron Obstruct Pulmon Dis. 2014;9:569–576.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67:957–963.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Vestbo J, Anderson JA, et al. Effect of fluticasone furoate and vilanterol on exacerbations of chronic obstructive pulmonary disease in patients with moderate airflow obstruction. Am J Respir Crit Care Med. 2017;195:881–888.
   PubMed Web of Science ®Google Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014 Mar 10;3:CD010115.
   PubMed Web of Science ®Google Scholar
• Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol. 2007;98:225–238.
   PubMed Web of Science ®Google Scholar
• Jones PW. St. George’s Respiratory Questionnaire: MCID. COPD. 2005;2:75–79.
   PubMedGoogle Scholar
• Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
   PubMed Web of Science ®Google Scholar
• Stanford RH, Parker ED, Reinsch TK, et al. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA. Respir Med. 2019;150:1–7.
   PubMed Web of Science ®Google Scholar
• Janson C, Stratelis G, Miller-Larsson A, et al. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:3055–3064.
   PubMed Web of Science ®Google Scholar
• van Den Berge M, Jonker MR, Miller-Larsson A, et al. Effects of fluticasone propionate and budesonide on the expression of immune defense genes in bronchial epithelial cells. Pulm Pharmacol Ther. 2018;50:47–56.
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Poole P, Milan SJ, et al. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 Nov 10;11:CD003794.
   PubMedGoogle Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789.
   PubMed Web of Science ®Google Scholar
• Price D, Bateman ED, Chisholm A, et al. Complementing the randomized controlled trial evidence base. Evolution not revolution. Ann Am Thorac Soc. 2014;11(Suppl 2):S92–8.
   PubMedGoogle Scholar
• Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365:82–93.
   PubMed Web of Science ®Google Scholar
• Silverman SL. From randomized controlled trials to observational studies. Am J Med. 2009;122:114–120.
   PubMed Web of Science ®Google Scholar
• Festic E, Bansal V, Gupta E, et al. Association of inhaled corticosteroids with incident Pneumonia and mortality in COPD patients; systematic review and meta-analysis. COPD. 2016;13:312–326.
   PubMedGoogle Scholar
• Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123:1001–1006.
   PubMed Web of Science ®Google Scholar
• Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011;66:699–708.
   PubMed Web of Science ®Google Scholar